文献速递慢性肾脏病肾小球疾病

VEGFR1阻断抗体改善糖尿病小鼠内皮结构、肾功能及GFR

Vascular Endothelial Growth Factor Receptor 1-Blocking Antibody Improves Endothelial Structure, Kidney Function, and GFR in Diabetic Mice.
PubMed 文献 · J Am Soc Nephrol · 2026-07-20

研究探讨内源性VEGFA不足是否参与糖尿病肾病(DKD),并在小鼠模型中测试VEGFR1阻断抗体VGFB1的效应。结果显示VGFB1改善白蛋白尿、血清肌酐、GFR及肾脏结构,机制与赖诺普利不同,涉及增加内皮窗孔和糖萼相关基因。

要点

  • DKD患者循环可溶性Flt1和PlGF升高,肾内VEGFA mRNA降低。
  • VEGFR1阻断抗体VGFB1改善糖尿病小鼠肾功能、白蛋白尿和肾脏结构。
  • VGFB1机制与赖诺普利不同,涉及增加内皮窗孔和糖萼相关基因。

核心结论

  • 抗VEGFR1抗体可恢复严重小鼠DKD的VEGFA活性、内皮健康和GFR,机制与赖诺普利不同。

研究设计与样本

  • 在人DKD血浆样本(来自CREDENCE试验)中检测可溶性VEGFR1、VEGFA和PlGF。
  • 在单肾切除+肾素表达AAV+db/db糖尿病肾病小鼠中测试鼠源化抗小鼠VEGFR1阻断抗体VGFB1。
  • 比较VGFB1或赖诺普利治疗小鼠的肾脏组织学、透射电镜和RNA测序。

主要发现

  • CREDENCE参与者中eGFR较低者循环可溶性Flt1和PlGF较高,肾内VEGFA mRNA随eGFR降低而减少。
  • VGFB1改善单肾切除+肾素表达AAV+db/db小鼠的整体sinistrin清除率、血清肌酐、白蛋白尿、血压和肾脏结构。
  • VGFB1较赖诺普利显著增加肾小球内皮基因Emcn、Esm1、Ehd3和Exoc3l2。

关键数值与推荐

  • CREDENCE参与者中eGFR较低者循环可溶性Flt1和PlGF较高,肾内VEGFA mRNA随eGFR降低而减少。

临床怎么用

  • VEGFR1阻断可能成为DKD治疗新策略,但需进一步临床研究验证。

局限性

  • 研究主要基于小鼠模型,人类数据仅为观察性关联。
  • VGFB1为鼠源化抗体,尚未在人体中验证安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: We found evidence for reduced vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 activation in both human and mouse diabetic kidney disease. A monoclonal vascular endothelial growth factor receptor 1-blocking antibody improved urine albumin-creatinine ratio and GFR in a mouse model of accelerated diabetic kidney disease. The mechanism for this benefit appears to be linked to increased endogenous vascular endothelial growth factor A and differentiates from lisinopril. BACKGROUND: Diabetic kidney disease (DKD) remains the major cause of kidney failure. Vascular endothelial growth factor A (VEGFA)-neutralizing antibodies also cause kidney disease in normal people. The present studies explored whether endogenous VEGFA deficiency might contribute to DKD. METHODS: Plasma soluble vascular endothelial growth factor receptor 1 (VEGFR1; aka sflt1), the VEGFR1 ligands VEGFA, and placental growth factor were measured in human DKD plasma samples from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We also tested the effects of monoclonal antibody designation for murinized anti-mouse VEGFR1 receptor (VGFB1), a murinized VEGFR1-blocking antibody in the uninephrectomy renin expressing adeno-associated virus db/db DKD mouse including translational end points of serum creatinine and overall survival. Histology, transmission electron microscopy, and RNA sequencing of mouse kidneys treated with or without VGFB1 or lisinopril were compared. RESULTS: Circulating soluble Flt1 and placental growth factor were higher in CREDENCE participants with lower eGFR, while intrarenal VEGFA mRNA decreased with lower eGFR. VEGFR1 blockade with the VGFB1 mAb improved overall sinistrin clearance, serum creatinine, albuminuria, BP, and kidney structure in uninephrectomy renin expressing adeno-associated virus db/db mice. VGFB1 treatment benefit differentiated from lisinopril by increasing endothelial fenestrae and glycocalyx-related genes. Compared with lisinopril, VGFB1 also significantly increased glomerular endothelial genes including Emcn, Esm1, Ehd3, and Exoc3l2. CONCLUSIONS: An anti-VEGFR1 antibody restored VEGFA activity, endothelial health, and GFR in severe murine DKD. This effect was via a mechanism distinct from lisinopril.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Li J, Gonzalez Villalobos RA, Rutkoski TJ, et al. Vascular Endothelial Growth Factor Receptor 1-Blocking Antibody Improves Endothelial Structure, Kidney Function, and GFR in Diabetic Mice. J Am Soc Nephrol. 2026. PMID: 42475421. doi:10.1681/ASN.0000001176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。